Exportar registro bibliográfico


Metrics:

Resistant hypertension: time to consider the best fifth anti-hypertensive treatment (2018)

  • Authors:
  • USP affiliated authors: DRAGER, LUCIANO FERREIRA - FM
  • Unidades: FM
  • DOI: 10.1007/s11906-018-0866-y
  • Subjects: HIPERTENSÃO; ESTUDOS MULTICÊNTRICOS; FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
  • Language: Inglês
  • Imprenta:
  • Source:
  • Online source accessDOI
    Informações sobre o DOI: 10.1007/s11906-018-0866-y (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      PIO-ABREU, Andrea; DRAGER, Luciano Ferreira. Resistant hypertension: time to consider the best fifth anti-hypertensive treatment. Current hypertension reports, New York, v. 20, n. 8, 2018. Disponível em: < http://dx.doi.org/10.1007/s11906-018-0866-y > DOI: 10.1007/s11906-018-0866-y.
    • APA

      Pio-abreu, A., & Drager, L. F. (2018). Resistant hypertension: time to consider the best fifth anti-hypertensive treatment. Current hypertension reports, 20( 8). doi:10.1007/s11906-018-0866-y
    • NLM

      Pio-abreu A, Drager LF. Resistant hypertension: time to consider the best fifth anti-hypertensive treatment [Internet]. Current hypertension reports. 2018 ; 20( 8):Available from: http://dx.doi.org/10.1007/s11906-018-0866-y
    • Vancouver

      Pio-abreu A, Drager LF. Resistant hypertension: time to consider the best fifth anti-hypertensive treatment [Internet]. Current hypertension reports. 2018 ; 20( 8):Available from: http://dx.doi.org/10.1007/s11906-018-0866-y

    Referências citadas na obra
    Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association professional education Committee of the Council for High Blood Pressure Research. Circulation 2008;117(25):e510–e526.
    Yugar-Toledo JC, Brunelli V, Vilela-Martin JF, Fattori A, Moreno H. Controlled versus uncontrolled resistant hypertension: are they in the same bag? Curr Hypertens Rep. 2018;20(3):26.
    Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046–58.
    • Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. (2017) ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017. https://doi.org/10.1161/HYP.0000000000000065 . This is the new AHA guidelines proposing a new cutoff for diagnosing and treating hypertension, including in those with resistant hypertension.
    Muiesan ML, Salvetti M, Rizzoni D, Paini A, Agabiti-Rosei C, Aggiusti C, et al. Resistant hypertension and target organ damage. Hypertens Res. 2013;36(6):485–91.
    Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42.
    Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Crowley K, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013;34(16):1204–14.
    Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53:646–53.
    •• Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (resistant hypertension optimal treatment). Hypertension. 2018;71(4):681–90. This multicentric trial compared spironolactone versus clonidine as a fourth drug therapy for patients with confirmed resistant hypertension. Blood pressure was evaluated by both office and 24-h ambulatory blood pressure monitoring.
    Václavík J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069–75. https://doi.org/10.1161/HYPERTENSIONAHA.111.169961 . Erratum in: Hypertension. 2015 Feb;65(2):e7
    •• Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68. The PATHWAY-2 evaluated the comparison of three anti-hypertensive drugs to select the best fourth option for patients with confirmed resistant hypertension. Home blood pressure was used in the analysis.
    Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens. 2015;28:1376–85.
    Rodilla E, Costa JA, Perez-Lahiguera F, et al. Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev Esp Cardiol. 2009;62:158–66.
    Oliveras A, Armario P, Clarà A, Sans-Atxer L, Vázquez S, Pascual J, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study—a randomized controlled trial. J Hypertens. 2016;34:1863–71.
    ReHOT Investigators, Krieger EM, Drager LF, Giorgi DM, Krieger JE, Pereira AC, et al. Resistant hypertension optimal treatment trial: a randomized controlled trial. Clin Cardiol. 2014;37(1):1–6. https://doi.org/10.1002/clc.22228 . Erratum in: Clin Cardiol. 2014Jun;37(6):388
    Louis WJ, McNeil JJ, Anavekar SN, Conway EL, Workman B, Howes LG, et al. Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents. J Cardiovasc Pharmacol. 1987;10(Suppl 12):S100–3.
    Lowenthal DT, Matzek KM, MacGregor TR. Clinical pharmacokinetics of clonidine. Clin Pharmacokinet. 1988;14:287–310.
    • Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res. 2015;116(6):1074–95. Comprehensive review discussing new therapies for treating hypertension.
    Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–70.
    Ng FL, Saxena M, Mahfoud F, Pathak A, Lobo MD. Device based therapy for hypertension. Curr Hypertens Rep. 2016;18:61.
    Fatureto-Borges F, Lorenzi-Filho G, Drager LF. Effectiveness of continuous positive airway pressure in lowering blood pressure in patients with obstructive sleep apnea: a critical review of the literature. Integr Blood Press Control. 2016;9:43–7.

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2020